The online platform providing early access to the latest drug innovations

Your access to promising drugs in development.


myTomorrows services in your country

Search Early Access Programs and Clinical Trials

How does myTomorrows work?

myTomorrows provides physicians and patients that are excluded from clinical trials access to innovative drugs in development. We focus on disease areas with unmet needs; oncology, neurology, psychiatry and rare diseases. myTomorrows identifies innovative drugs, informs physicians and patients and facilitates requests for access to these drugs in development.

identify drugs


Our physicians and bio-medical specialists identify the latest drug innovations from across the globe. Drugs that are offered on the platform have either shown promising results in clinical trials or are approved elsewhere in the world.

inform physicians


Physicians and pharmacists can register online and request information about the innovative drugs myTomorrows provides access to. On request physicians can explore clinical trial results, mode of action and dosing of the drugs.

Patients can also register and request access to specific patient information.

facilitate health care


In most countries health authorities must grant permission for treatment.
myTomorrows facilitates requests for permission for physicians and pharmacists. After approval by the health authorities, myTomorrows ensures timely supply of the requested drug from drug developers across the globe to the relevant pharmacist, and subsequently the patient.

Please share: 

"When my father had no more treatment options and was dying of lung cancer I could have given him access to promising unapproved therapies because I worked in the biotech industry. When he passed away I realised how unfair it was that only I had that option. That's why I founded myTomorrows."

− Ronald Brus MD

Featured in:

myTomorrows is a Dutch startup that wants to disrupt the way patients with unmet medical needs access development-stage treatments

myTomorrows in Le Monde newspaper

Business Insider